These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26208569)

  • 1. Iron Chelation in Patients with Transfusion Dependent Thalassemia: An Insight on Response to Deferasirox.
    Shaikh MS; Adil SN
    J Coll Physicians Surg Pak; 2015 Jul; 25(7):553-4. PubMed ID: 26208569
    [No Abstract]   [Full Text] [Related]  

  • 2. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
    Jetsrisuparb A; Komvilaisak P; Wiangnon S; Jetsrisuparb C
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):400-3. PubMed ID: 20505533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
    Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
    Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
    Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R; Ahmed J; Krishnan P; Jankharia B
    Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
    Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
    Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB; Shah FT
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Fragomeno C; Roccabruna E; D'Ascola DG
    Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
    Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Habr D; Ros J; Zhu Z; Cappellini MD
    Ann Hematol; 2013 Nov; 92(11):1485-93. PubMed ID: 23775581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
    J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
    Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
    Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
    Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
    Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
    Piga A; Longo F; Origa R; Roggero S; Pinna F; Zappu A; Castiglioni C; Cappellini MD
    Br J Haematol; 2014 Nov; 167(3):423-6. PubMed ID: 24976388
    [No Abstract]   [Full Text] [Related]  

  • 20. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.